Table 4.
Treatment-related AEs in patients receiving lenvatinib plus anti-PD-1 antibody (n = 30).
| Preferred AE Term | No. (%) | |||
|---|---|---|---|---|
| Any Gradea | Grade 1 | Grade 2 | Grade 3 | |
| Decrease in platelet count | 14 (46.7%) | 5 (16.7%) | 4 (13.3%) | 5 (16.7%) |
| Proteinuria | 10 (33.3%) | 1 (3.3%) | 6 (20.0%) | 3 (10.0%) |
| Decrease in white blood cell count | 8 (26.7%) | 2 (6.7%) | 3 (10.0%) | 3 (10.0%) |
| Hypertension | 6 (20.0%) | 0 | 4 (13.3%) | 2 (6.7%) |
| Hypothyroidism | 5 (16.7%) | 3 (10.0%) | 0 | 2 (6.7%) |
| Palmar-plantar erythrodysesthesia syndrome | 4 (13.3%) | 1 (3.3%) | 1 (3.3%) | 2 (6.7%) |
| Increased transaminase | 4 (13.3%) | 0 | 2 (6.7%) | 2 (6.7%) |
| Weight decreased | 3 (10.0%) | 0 | 3 (10%) | 0 |
| Hypoadrenalism | 3 (10.0%) | 0 | 0 | 3 (10.0%) |
| Myocarditis | 3 (10.0%) | 2 (6.7%) | 0 | 1 (3.3%) |
| Gastrointestinal bleeding | 2 (6.7%) | 0 | 0 | 2 (6.7%) |
| Hyperthyroidism | 2 (6.7%) | 2 (6.7%) | 0 | 0 |
| Abdominal distension | 2 (6.7%) | 2 (6.7%) | 0 | 0 |
aAdverse events were graded in accordance with the Common Terminology Criteria for Adverse Events v4.0.